Klaria advances collaboration with BDO's Life Science M&A team through launch in Europe and completed strategic US plan
Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") today publishes a status update regarding licensing partner CNX Therapeutics' ("CNX") upcoming launch of Sumatriptan Alginate Film ("SAF") for migraine treatment in Europe, Klaria's completed strategic plan for a potential US launch with a partner, and how these activities will advance the collaboration with BDO's UK Life Science M&A team ("BDO") to sign licensing agreements, or complete other transactions to maximize shareholder value, for markets outside Europe such as the US and globally.
Klaria is in a crucial phase in the